Published in Oncotarget on August 01, 2012
TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients. J Clin Invest (2015) 1.22
Oncolytic polio virotherapy of cancer. Cancer (2014) 1.05
Increased Soluble CD155 in the Serum of Cancer Patients. PLoS One (2016) 0.82
Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy. Front Immunol (2016) 0.78
Melanoma: clinical features and genomic insights. Cold Spring Harb Perspect Med (2014) 0.77
Specific c-Jun target genes in malignant melanoma. Cancer Biol Ther (2016) 0.75
NF‑κB inhibition is associated with OPN/MMP‑9 downregulation in cutaneous melanoma. Oncol Rep (2017) 0.75
Late Onset Achromatic Melanoma Arising in a Giant Congenital Melanocytic Nevus. Open Access Maced J Med Sci (2017) 0.75
Hoigne Syndrome Caused by Intralesional Meglumine Antimoniate. Open Access Maced J Med Sci (2017) 0.75
CD155, an onco-immunologic molecule in human tumors. Cancer Sci (2017) 0.75
A Misleading Anamnesis: Learning To Suspect. Open Access Maced J Med Sci (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell (1989) 9.82
The poliovirus receptor protein is produced both as membrane-bound and secreted forms. EMBO J (1990) 3.31
Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res (2005) 3.30
The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany NY) (2010) 3.27
The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics (2008) 3.11
The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A (2005) 3.05
Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation. Nat Rev Mol Cell Biol (2008) 2.93
TGFβ-induced c-Myb affects the expression of EMT-associated genes and promotes invasion of ER+ breast cancer cells. Cell Cycle (2011) 2.41
Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res (2008) 1.99
Cutaneous malignant melanoma. Mayo Clin Proc (2006) 1.88
Disruption of E-cadherin by matrix metalloproteinase directly mediates epithelial-mesenchymal transition downstream of transforming growth factor-beta1 in renal tubular epithelial cells. Am J Pathol (2009) 1.75
Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev (1999) 1.72
CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer (2004) 1.48
Overexpression of the CD155 gene in human colorectal carcinoma. Gut (2001) 1.40
Epithelial-mesenchymal transition: NF-kappaB takes center stage. Cell Cycle (2004) 1.38
Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol (2009) 1.38
The involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle (2009) 1.38
Tracking the intermediate stages of epithelial-mesenchymal transition in epithelial stem cells and cancer. Cell Cycle (2011) 1.34
Nectins and nectin-like molecules: roles in cell adhesion, polarization, movement, and proliferation. IUBMB Life (2006) 1.32
The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma. Cancer (2001) 1.25
Poliovirus receptor CD155-targeted oncolysis of glioma. Neuro Oncol (2004) 1.23
The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence. Aging (Albany NY) (2009) 1.19
New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget (2011) 1.15
PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Mol Immunol (2005) 1.11
The various roles of ubiquitin in Wnt pathway regulation. Cell Cycle (2010) 1.08
Yin yang 1 expression in human tumors. Cell Cycle (2010) 1.07
Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus. Clin Cancer Res (2004) 1.05
Overexpression of TWIST2 correlates with poor prognosis in head and neck squamous cell carcinomas. Oncotarget (2011) 1.04
Enhancement of serum- and platelet-derived growth factor-induced cell proliferation by Necl-5/Tage4/poliovirus receptor/CD155 through the Ras-Raf-MEK-ERK signaling. J Biol Chem (2004) 1.04
E-cadherin expression in human melanoma. Melanoma Res (1996) 1.00
Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells. Neoplasia (2010) 0.97
Surface expression of precursor N-cadherin promotes tumor cell invasion. Neoplasia (2010) 0.95
Cross-talk among integrin, cadherin, and growth factor receptor: roles of nectin and nectin-like molecule. Int Rev Cytol (2008) 0.95
Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma. Cancer Sci (2010) 0.94
Pathways of oncogene-induced senescence in human melanocytic cells. Cell Cycle (2010) 0.93
Yin Yang 1 overexpression in diffuse large B-cell lymphoma is associated with B-cell transformation and tumor progression. Cell Cycle (2010) 0.93
Transcriptional activation of the mouse Necl-5/Tage4/PVR/CD155 gene by fibroblast growth factor or oncogenic Ras through the Raf-MEK-ERK-AP-1 pathway. Oncogene (2005) 0.93
Necl-5/poliovirus receptor interacts in cis with integrin alphaVbeta3 and regulates its clustering and focal complex formation. J Biol Chem (2007) 0.92
Constitutive expression of the alpha4 integrin correlates with tumorigenicity and lymph node metastasis of the B16 murine melanoma. Neoplasia (2010) 0.90
Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunol Immunother (2009) 0.90
Inhibition of Necl-5 (CD155/PVR) reduces glioblastoma dispersal and decreases MMP-2 expression and activity. J Neurooncol (2010) 0.89
Caveolin-1 promotes pancreatic cancer cell differentiation and restores membranous E-cadherin via suppression of the epithelial-mesenchymal transition. Cell Cycle (2011) 0.87
The emerging role of the thrombin receptor (PAR-1) in melanoma metastasis--a possible therapeutic target. Oncotarget (2011) 0.87
Co-regulated expression of matrix metalloproteinase-2 and transforming growth factor-beta in melanoma development and progression. Oncol Rep (2010) 0.85
Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma. Oncotarget (2011) 0.84
Modulation of YY1 and p53 expression by transforming growth factor-β3 in prostate cell lines. Cytokine (2011) 0.82
Early detection of melanoma: the best strategy for a favorable prognosis. Clin Dermatol (2002) 0.81
Involvement of heterophilic trans-interaction of Necl-5/Tage4/PVR/CD155 with nectin-3 in formation of nectin- and cadherin-based adherens junctions. Genes Cells (2004) 0.81
State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal Cancer. Cancer (2008) 0.80
[Nectin and nectin-like molecules as markers, actors and targets in cancer]. Med Sci (Paris) (2010) 0.80
Exploration of target molecules for prostate cancer gene therapy. Prostate (2007) 0.80
The precursors of malignant melanoma. Recent Results Cancer Res (2002) 0.77
Thick cutaneous malignant melanoma: a reappraisal of prognostic factors. Melanoma Res (2000) 0.76
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta (2006) 7.33
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 3.43
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul (2006) 3.32
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) (2011) 2.72
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget (2012) 1.96
Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). Int J Oncol (2003) 1.91
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 1.85
Senescence-associated exosome release from human prostate cancer cells. Cancer Res (2008) 1.78
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget (2010) 1.64
HCV-associated B cell clonalities in the liver do not carry the t(14;18) chromosomal translocation. Hepatology (2005) 1.57
GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget (2014) 1.56
Cross-reactivity of Anisakis simplex: possible role of Ani s 2 and Ani s 3. Int J Dermatol (2007) 1.55
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget (2012) 1.55
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle (2009) 1.54
Inhibition of the CaM-kinases augments cell death in response to oxygen radicals and oxygen radical inducing cancer therapies in MCF-7 human breast cancer cells. Cancer Biol Ther (2006) 1.48
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res (2010) 1.46
EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). Int J Oncol (2003) 1.43
B-raf and insulin synergistically prevent apoptosis and induce cell cycle progression in hematopoietic cells. Cell Cycle (2004) 1.43
Akt as a therapeutic target in cancer. Expert Opin Ther Targets (2008) 1.41
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol (2011) 1.40
Redox regulation of the calcium/calmodulin-dependent protein kinases. J Biol Chem (2004) 1.39
The involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle (2009) 1.38
The tumor microenvironment in hepatocellular carcinoma (review). Int J Oncol (2012) 1.38
Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs (2009) 1.36
Trombiculiasis: clinical contribution. Eur J Dermatol (2005) 1.35
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget (2012) 1.34
Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). Int J Oncol (2011) 1.34
State of the art in antigen retrieval for immunohistochemistry. J Immunol Methods (2008) 1.33
Melanoma: molecular pathogenesis and emerging target therapies (Review). Int J Oncol (2009) 1.31
Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells. Cell Cycle (2004) 1.30
The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. Biochim Biophys Acta (2010) 1.30
Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res (2009) 1.29
Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res (2004) 1.28
Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle (2008) 1.25
Solid pseudopapillary tumour of the pancreas. Lancet Oncol (2003) 1.24
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. Oncotarget (2012) 1.23
Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. Oncogene (2003) 1.21
Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res (2004) 1.20
The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle (2010) 1.18
Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1-expressing cells to imatinib and geldanamycin. Cancer Biol Ther (2005) 1.17
Tobacco smoking, alcohol drinking, and the risk of different histological types of nasopharyngeal cancer in a low-risk population. Oral Oncol (2011) 1.17
Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle (2011) 1.17
Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin Cancer Res (2008) 1.16
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget (2011) 1.16
Emerging MEK inhibitors. Expert Opin Emerg Drugs (2010) 1.16
Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res (2003) 1.15
Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. Oncotarget (2014) 1.14
Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. Oncotarget (2011) 1.14
The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit. Genes Cancer (2010) 1.14
Integrin signaling links protein kinase Cepsilon to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells. Oncogene (2004) 1.13
Gastrointestinal carcinoid tumor and chylous ascites, a rare association with a poor prognosis. A case report. Tumori (2008) 1.12
Solubility and bioactivity of the Pseudomonas quinolone signal are increased by a Pseudomonas aeruginosa-produced surfactant. Infect Immun (2005) 1.11
Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a. Cell Cycle (2012) 1.11
Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle (2005) 1.10
Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. Vasc Med (2005) 1.09
Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist Updat (2007) 1.08
A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. Cell Cycle (2007) 1.08
Advances in targeting signal transduction pathways. Oncotarget (2012) 1.06
Methylenetetrahydrofolate reductase 677 C-->T polymorphism and risk of proximal colon cancer in north Italy. Clin Cancer Res (2003) 1.05
Role of hypoxia and autophagy in MDA-MB-231 invasiveness. J Cell Physiol (2010) 1.05
Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Res (2008) 1.04
Calcium/calmodulin-dependent kinase I and calcium/calmodulin-dependent kinase kinase participate in the control of cell cycle progression in MCF-7 human breast cancer cells. Cancer Res (2005) 1.04
The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. Expert Opin Ther Targets (2004) 1.03
The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy. Oncotarget (2013) 1.03